| Name | Title | Contact Details |
|---|---|---|
Sonya Natanzon |
VP of Engineering | Profile |
Darya Chudova |
Chief Technology Officer | Profile |
Kim Green |
Director, Information Security and Compliance | Profile |
Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.
Superhuman hair. Engineered from nature.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
KBI BioPharma is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baptist Retirement Communities of Georgia is a Decatur, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.